– Gavel brings highly relevant CAR T experience from Legend Biotech where he led the launch and commercialization of CARVYKTI® from 2018 until 2025 – PHILADELPHIA, Oct. 14, 2025 (GLOBE…
On track to initiate TRX319 Phase 1/2a dose-escalation trial in early 2026 TRX319 is an allogeneic CAR-Tr1 Treg cell therapy designed to pair targeted B-cell control with active anti-inflammatory signaling…
Award recognizes technology breakthroughs that promise to help define the future of their industries NEW YORK, Oct. 14, 2025 (GLOBE NEWSWIRE) — Precision Neuroscience Corporation (Precision), a leader in brain–computer…
Milestone strengthens the company’s leadership in advanced IOL innovation FINEVISION HP, with millions of implantations worldwide, will now be available to U.S. patients Proprietary design features anchor the launch of…
Greater than 90% depletion of B cells within 12 hours of a single dose of AAN-14x Multiple redosing of AAN-14x at desired intervals with no evidence of hepatic or other…
― Preclinical data of FTX-6274 suggests potential for the treatment of castration resistant prostate cancer ― CAMBRIDGE, Mass., Oct. 14, 2025 (GLOBE NEWSWIRE) — Fulcrum Therapeutics, Inc.® (Fulcrum) (Nasdaq: FULC),…
SAN DIEGO, Oct. 14, 2025 (GLOBE NEWSWIRE) — Gyre Therapeutics (“Gyre”) (Nasdaq: GYRE), an innovative, commercial-stage biopharmaceutical company dedicated to advancing fibrosis-first therapies across organ systems affected by chronic disease,…
CHATHAM, N.J., Oct. 14, 2025 (GLOBE NEWSWIRE) — Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (“Tonix” or the “Company”), a fully integrated biotechnology company with marketed products and a pipeline of…
– Deal to add navenibart, a late-stage and long-acting plasma kallikrein inhibitor, in Phase 3 clinical development, to BioCryst’s HAE portfolio – – Solidifies double digit growth trajectory for HAE…
Purespring Therapeutics to Present at Chardan’s 9th Annual Genetic Medicines Conference London – 14 October 2025 – Purespring Therapeutics, a precision nephrology company focused on transforming the treatment of kidney…